Autonomous AI to mitigate disparities for diabetic retinopathy screening in youth during and after COVID-19
Autonomous AI to mitigate disparities for diabetic retinopathy screening in youth during and after COVID-19
批准号:
10689400
负责人:
Risa Michelle Wolf
金额:
$20.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-01 至 2024-08-31
关键词:
AddressAdministrative SupplementAdultAffectAgeArtificial IntelligenceAwardBlindnessCOVID-19COVID-19 impactCaringChildChildhoodChildhood diabetesClinicClinicalClinical DataClinical TrialsCommunitiesComplications of Diabetes MellitusComputer softwareConsensusCost SavingsDataData SetDecision ModelingDetectionDiabetes MellitusDiabetic RetinopathyEarly DiagnosisEffectivenessEvaluationExpert SystemsEyeFDA approvedFoundationsFundingFundus photographyFutureHealthHealth Services AccessibilityHealth TechnologyHealthcare SystemsHouseholdImprove AccessIncomeInfrastructureInstitutionInsulin-Dependent Diabetes MellitusInsuranceInternetInterventionLow incomeMedicaidMethodsMinorityMulticenter StudiesNon-Insulin-Dependent Diabetes MellitusOphthalmic examination and evaluationOphthalmologistParentsParticipantPatient-Focused OutcomesPatientsPediatricsPersonsPilot ProjectsPopulationPrevalenceRandomized Controlled TrialsResearch PersonnelRiskSafetyScreening ResultSiteSystemTechnologyTelemedicineTimeUnited States National Institutes of HealthYouthadherence ratearmbehavioral economicscare outcomescostcost effectivecost effectivenessdiabeticdigital healthcaredisparity eliminationexperiencefollow-uphealth care deliveryhigh riskimprovedinnovationminority childrenmultidisciplinarypandemic diseasepoint of carepreventprospectiveracial biasresponseretinal imagingroutine careroutine screeningscreeningscreening guidelinessocialsocioeconomicsstandard of caresuccessunderserved communityunderserved minority
中文摘要
项目总结
英文摘要
Project Summary
Diabetic retinopathy affects 4-15% of youth with type 1 and type 2 diabetes and is a leading cause of
blindness in adults as early as age 20. Yearly screening for DR is recommended, but only 35-72% of youth
undergo screening, with minority youth and children from lower socioeconomic backgrounds less likely to
undergo screening. Early detection of DR through screening prevents progression to vision loss. The current
standard of care for pediatric DR screening is referral to an ECP for a dilated eye exam. In 2018, the FDA
approved the first autonomous artificial intelligence (AI) software that interprets retinal images taken with a
non-mydriatic fundus camera, providing an immediate result for DR screening at the point of care (POC) for
adults with diabetes. In a pilot study at our institution, we were the first to implement this technology in
pediatrics, demonstrating safety, effectiveness and equity, and cost-savings to the patient. We also found that
minority youth, those with lower household income and Medicaid insurance were less likely to undergo
recommended screening, yet were more likely to have DR.
We hypothesize that implementing POC autonomous AI in the diabetes care setting will
increase DR screening rates in youth with diabetes, mitigate disparities in access to screening, and be
cost-effective to the health care system. In the parent award, Aim1 is a randomized control trial at two
clinic sites to determine if autonomous AI increases screening compared to ECP, and if those who screen
positive by AI are more likely to go for follow-up at the ECP. Aim2 is a prospective observational trial of AI
screening to determine if AI mitigates disparities in screening, and improves the proportion of at-risk, minority
and low income, youth who go for follow-up if their AI screen is positive. In Aim 3, we will use a decision model
to determine if AI is cost-effective and cost-savings to the health care system.
If AI is shown to increase screening rates while mitigating disparities in access to care, it has the
potential to reshape screening methods now and in the future, and will have a major impact on improving care
for underserved minority and low-income youth.
In this administrative supplement to the parent award, we are requesting additional support to conduct
the aims of the parent award and disseminate the results, as well as funds to create a high-quality
prospectively collected dataset of pediatric retinal images with corresponding clinical data that can be utilized
by other investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autonomous AI to mitigate disparities for diabetic retinopathy screening in youth during and after COVID-19
-
批准号:10598686
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2021
-
负责人:Risa Michelle Wolf
-
依托单位:
Autonomous AI to mitigate disparities for diabetic retinopathy screening in youth during and after COVID-19
-
批准号:10309013
-
项目类别:
-
资助金额:$49.48万
-
财政年份:2021
-
负责人:Risa Michelle Wolf
-
依托单位:
海外基金